<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS One</journal-id><journal-id journal-id-type="iso-abbrev">PLoS ONE</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="pmc">plosone</journal-id><journal-title-group><journal-title>PLoS ONE</journal-title></journal-title-group><issn pub-type="epub">1932-6203</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">19415120</article-id><article-id pub-id-type="pmc">2673582</article-id><article-id pub-id-type="publisher-id">08-PONE-RA-07257R2</article-id><article-id pub-id-type="doi">10.1371/journal.pone.0005318</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline"><subject>Pediatrics and Child Health</subject><subject>Infectious Diseases/Protozoal Infections</subject><subject>Infectious Diseases/Tropical and Travel-Associated Diseases</subject></subj-group></article-categories><title-group><article-title>Strong Gametocytocidal Effect of Methylene Blue-Based Combination Therapy against Falciparum Malaria: A Randomised Controlled Trial</article-title><alt-title alt-title-type="running-head">Methylene Blue and Malaria</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Coulibaly</surname><given-names>Boubacar</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Zoungrana</surname><given-names>Augustin</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Mockenhaupt</surname><given-names>Frank P.</given-names></name><xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Schirmer</surname><given-names>R. Heiner</given-names></name><xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Klose</surname><given-names>Christina</given-names></name><xref ref-type="aff" rid="aff4">
<sup>4</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Mansmann</surname><given-names>Ulrich</given-names></name><xref ref-type="aff" rid="aff5">
<sup>5</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Meissner</surname><given-names>Peter E.</given-names></name><xref ref-type="aff" rid="aff6">
<sup>6</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>M&#x000fc;ller</surname><given-names>Olaf</given-names></name><xref ref-type="aff" rid="aff6">
<sup>6</sup>
</xref><xref ref-type="corresp" rid="cor1">
<sup>&#x0002a;</sup>
</xref></contrib></contrib-group><aff id="aff1">
<label>1</label>
<addr-line>Centre de Recherche en Sant&#x000e9; de Nouna, Nouna, Burkina Faso</addr-line>
</aff><aff id="aff2">
<label>2</label>
<addr-line>Institute of Tropical Medicine and International Health, Charit&#x000e9; &#x02013; University Medicine Berlin, Berlin, Germany</addr-line>
</aff><aff id="aff3">
<label>3</label>
<addr-line>Biochemistry Centre, Ruprecht-Karls-University, Heidelberg, Germany</addr-line>
</aff><aff id="aff4">
<label>4</label>
<addr-line>Institute of Medical Biometrics and Informatics, Medical School, Ruprecht-Karls-University, Heidelberg, Germany</addr-line>
</aff><aff id="aff5">
<label>5</label>
<addr-line>Institute of Bioinformatics and Epidemiology, Medical School, Ludwig Maximilians University M&#x000fc;nchen, Germany</addr-line>
</aff><aff id="aff6">
<label>6</label>
<addr-line>Department of Tropical Hygiene and Public Health, Medical School, Ruprecht-Karls-University, Heidelberg, Germany</addr-line>
</aff><contrib-group><contrib contrib-type="editor"><name><surname>Gregson</surname><given-names>Aric</given-names></name><role>Editor</role><xref ref-type="aff" rid="edit1"/></contrib></contrib-group><aff id="edit1">University of California Los Angeles, United States of America</aff><author-notes><corresp id="cor1">&#x0002a; E-mail: <email>olaf.mueller@urz.uni-heidelberg.de</email></corresp><fn fn-type="con"><p>Conceived and designed the experiments: FPM RHS UM PM OM. Performed the experiments: BC AZ. Analyzed the data: BC AZ FPM CK UM OM. Contributed reagents/materials/analysis tools: BC. Wrote the paper: BC AZ FPM RHS CK UM PM OM.</p></fn></author-notes><pub-date pub-type="collection"><year>2009</year></pub-date><pub-date pub-type="epub"><day>5</day><month>5</month><year>2009</year></pub-date><volume>4</volume><issue>5</issue><elocation-id>e5318</elocation-id><history><date date-type="received"><day>9</day><month>11</month><year>2008</year></date><date date-type="accepted"><day>23</day><month>3</month><year>2009</year></date></history><permissions><copyright-statement>Coulibaly et al.</copyright-statement><copyright-year>2009</copyright-year><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.</license-p></license></permissions><abstract><sec><title>Background</title><p>With the availability of new preventive and curative interventions, global malaria control has been strengthened significantly in recent years. Drugs effective in reducing malaria gametocytaemia might contribute to local elimination and possible long-term eradication. We here report on the effects of methylene blue (MB)-based malaria combination therapy on gametocytaemia during a randomised-controlled trial in Burkina Faso.</p></sec><sec><title>Methods</title><p>An open-label randomised controlled phase II study in 180 children aged 6&#x02013;10 years with uncomplicated falciparum malaria was conducted in Nouna, north-western Burkina Faso. Children were randomised to MB&#x02013;artesunate (AS), MB&#x02013;amodiaquine (AQ), and AS-AQ (local standard of care). Overall follow-up was for 28 days, follow-up for gametocytaemia was for 14 days.</p></sec><sec><title>Findings</title><p>The treatment groups were similar in baseline characteristics and there was only one loss to follow-up. Compared to AS-AQ, both MB-containing regimens were associated with significantly reduced gametocyte carrier rates during follow-up days 3, 7, and 14. This effect was seen both in patients with and without <italic>P. falciparum</italic> gametocytaemia at baseline.</p></sec><sec><title>Interpretation</title><p>MB reveals pronounced gametocytocidal activity which appears to act against both existing and developing <italic>P. falciparum</italic> gametocytes. MB-based combination therapy thus has the potential to reduce transmission of <italic>P. falciparum</italic> malaria in endemic regions, which has important implications for future elimination and eradication strategies.</p></sec><sec><title>Trial Registration</title><p>ClinicalTrials.gov <ext-link ext-link-type="uri" xlink:href="http://clinicaltrials.gov/ct2/show/NCT00354380">NCT00354380</ext-link>
</p></sec></abstract><counts><page-count count="6"/></counts></article-meta></front><body><sec id="s1"><title>Introduction</title><p>Malaria remains the most important parasitic disease globally, and in Sub-Saharan Africa (SSA) in particular <xref rid="pone.0005318-Greenwood1" ref-type="bibr">[1]</xref>. New or rediscovered interventions such as insecticide-treated mosquito nets <xref rid="pone.0005318-Lengeler1" ref-type="bibr">[2]</xref>, artemisinin-based combination therapy (ACT) <xref rid="pone.0005318-Adjuik1" ref-type="bibr">[3]</xref>, and vaccines <xref rid="pone.0005318-Aponte1" ref-type="bibr">[4]</xref>, together with substantially increased funding are promising in terms of improved malaria control and possibly, eradication <xref rid="pone.0005318-Sachs1" ref-type="bibr">[5]</xref>&#x02013;<xref rid="pone.0005318-Tanner1" ref-type="bibr">[8]</xref>. In fact, as a consequence of a large-scale rollout of available interventions, major reductions in malaria morbidity and, partially, child mortality have recently been observed in areas of Kenya, Tanzania and Ethiopia <xref rid="pone.0005318-Fegan1" ref-type="bibr">[9]</xref>&#x02013;<xref rid="pone.0005318-Samarasekera1" ref-type="bibr">[11]</xref>.</p><p>Gametocytocidal antimalarials, and the artemisinines in particular, may accelerate such progress in that they reduce post-treatment transmission <xref rid="pone.0005318-Price1" ref-type="bibr">[12]</xref>&#x02013;<xref rid="pone.0005318-Garner1" ref-type="bibr">[14]</xref>. Yet, artemisinin derivatives do not prevent post-treatment transmission completely <xref rid="pone.0005318-Targett1" ref-type="bibr">[15]</xref>, and in view of emerging ACT resistance in South-East Asia <xref rid="pone.0005318-Duffy1" ref-type="bibr">[16]</xref>&#x02013;<xref rid="pone.0005318-Noedl1" ref-type="bibr">[18]</xref>, alternative drugs effective against gametocytes are urgently needed. Methylene blue (MB), the first synthetic drug ever used against malaria <xref rid="pone.0005318-Guttmann1" ref-type="bibr">[19]</xref>, has received renewed attention in recent years <xref rid="pone.0005318-Schirmer1" ref-type="bibr">[20]</xref>. MB is a subversive substrate and specific inhibitor of the <italic>P. falciparum</italic> disulfide reductases and in addition inhibits the parasite's heme detoxification <xref rid="pone.0005318-Schirmer1" ref-type="bibr">[20]</xref>, <xref rid="pone.0005318-Buchholz1" ref-type="bibr">[21]</xref>. MB in combination with a number of partner drugs has been shown to be safe and effective in a West-African population with a high prevalence of glucose-6-phosphate dehydrogenase deficiency <xref rid="pone.0005318-Mandi1" ref-type="bibr">[22]</xref>&#x02013;<xref rid="pone.0005318-Zoungrana1" ref-type="bibr">[25]</xref>. Interestingly, plasmoquine, an antimalarial drug developed as a derivative MB, is known to be highly effective against gametocytes <xref rid="pone.0005318-Greenwood2" ref-type="bibr">[26]</xref>. In this context it is also worth mentioning that genes encoding the putative target proteins of MB <xref rid="pone.0005318-Schirmer1" ref-type="bibr">[20]</xref>, <xref rid="pone.0005318-Buchholz1" ref-type="bibr">[21]</xref> were present in the gametocyte-specific cDNA library originally established in Kaslow's laboratory (27). Against this background, we analysed the efficacy of MB-based combination therapy against gametocytes using data from a randomised controlled phase II study in Burkina Faso.</p></sec><sec id="s2"><title>Methods</title><p>The protocol for this trial and supporting CONSORT checklist are available as supporting information; see <xref ref-type="supplementary-material" rid="pone.0005318.s001">Checklist S1</xref> and <xref ref-type="supplementary-material" rid="pone.0005318.s002">Protocol S1</xref>.</p><p>The study was conducted in October/November 2006 in the urban research zone of the <italic>Centre de Recherche en Sant&#x000e9; de Nouna</italic> (CRSN) in Nouna Health District, north-western Burkina Faso. The area is highly endemic for malaria with most clinical cases occurring during or briefly after the rainy season which lasts from June until October <xref rid="pone.0005318-Rawlings1" ref-type="bibr">[27]</xref>. Despite an ACT policy since 2005, malaria control in the study area continues to be mainly based on home treatment with chloroquine (CQ) <xref rid="pone.0005318-Mller1" ref-type="bibr">[28]</xref>, <xref rid="pone.0005318-Kouyat1" ref-type="bibr">[29]</xref>.</p><sec id="s2a"><title>Study design and objectives</title><p>The study was an open label randomized controlled phase II trial on safety and efficacy of MB-artesunate (AS) and MB-amodiaquine (AQ) in children with uncomplicated falciparum malaria, with blinding only for the laboratory technicians involved. The primary objective was to investigate the safety of the combinations MB-AS and MB-AQ in children with uncomplicated falciparum malaria. The secondary objective was to determine the efficacy of these MB-based combinations in the treatment of children with uncomplicated falciparum malaria. The study was designed to have a statistical power of 80&#x00025; in order to detect a difference in the number of adverse events of at least 20&#x00025; among study groups that was significant at the five percent level <xref rid="pone.0005318-Zoungrana1" ref-type="bibr">[25]</xref>.</p><p>Post-treatment gametocyte carriage was initially not planned to examine and specified later as an additional secondary endpoint. The methodology of the trial has been published elsewhere <xref rid="pone.0005318-Zoungrana1" ref-type="bibr">[25]</xref>, and only key aspects are briefly repeated here.</p></sec><sec id="s2b"><title>Study population and procedures</title><p>Only children from Nouna town were participating in this study. Inclusion criteria were: age 6&#x02013;10 years, ability to swallow tablets, uncomplicated falciparum malaria (axillary temperature &#x02265;37.5&#x000b0;C and &#x02265;1,000 <italic>P. falciparum</italic> asexual parasites per &#x000b5;L blood), and written informed consent given by the parents/caretakers. Exclusion criteria were signs of severe malaria, any apparent other disease, and malaria treatment &#x02013; except CQ &#x02013; with western drugs and/or antibiotics with antimalarial potency during the preceding week.</p><p>180 children were randomly assigned to receive directly observed treatment with either MB-AS, MB-AQ, or AS-AQ. The latter is the official first-line antimalarial in Burkina Faso. MB (Urolene Blue&#x000ae;, Star Pharmaceuticals, USA) was given at a dose of 10 mg per kilogram of body weight twice daily over three days, AS (Artesunate, Guilin Pharmaceuticals Co., Ltd., PR China) at a dose of 4 mg per kilogram of body weight once daily over three days, and AQ (Essential Drug Store, Ministry of Health, Burkina Faso) at a dose of 10 mg per kilogram of body weight once daily over three days. Children with fever &#x02265;38.5&#x000b0;C received a standard dose of 10 mg per kilogram paracetamol tablets every 6 hours (Essential Drug Store, Ministry of Health, Burkina Faso) until symptoms subsided.</p><p>Follow-up of study children was for 28 days using a slightly modified version of the latest WHO protocol on antimalarial drug efficacy testing <xref rid="pone.0005318-WHO1" ref-type="bibr">[30]</xref>. Children were followed up on days 1, 2, 3, 7, 14, and 28. Mothers and caretakers were encouraged to come back at any time between scheduled visits in case of unforeseen symptoms.</p><p>A finger-prick blood sample was taken on days 0, 2, 3, 7, 14, and 28, and during unscheduled visits. From this, malaria parasitaemia and haematocrit values were determined using standard CRSN procedures <xref rid="pone.0005318-Mller2" ref-type="bibr">[31]</xref>. Filter paper blood samples served as DNA source for PCR-based differentiation of recrudescences from reinfections <xref rid="pone.0005318-Zoungrana1" ref-type="bibr">[25]</xref>. Thick and thin blood films were examined by two experienced laboratory technicians supervised by one of the investigators (BC). Asexual parasites (and later gametocytes during slide re-examination) were counted on thick blood films against 200 white blood cells (WBCs) and parasite density was calculated assuming an average WBC count of 10,000/&#x000b5;L. Slides were declared negative if no parasites were seen in 400 fields on the thick film. For quality control, a 10&#x00025; random sample of blood films is regularly cross-checked at the Heidelberg School of Tropical Medicine, which has always demonstrated an overall high consistency between the different laboratory technicians with regard to parasite prevalence and density <xref rid="pone.0005318-Mller1" ref-type="bibr">[28]</xref>. After initial reading, all study slides were stored under controlled conditions in the laboratory of the CRSN.</p><p>In early 2008, all slides from the trial (only day 0 until day 14) were systematically re-examined by two experienced laboratory technicians supervised by one of the investigators (BC) for <italic>P. falciparum</italic> gametocytaemia prevalence and density, both in patients with ACPR and in patients without ACPR. In view of the short half-life of both AS and MB, these drugs would have no effect on new infections emerging after day 14. Thus, gametocytaemia occurring after day 14 was not considered.</p></sec><sec id="s2c"><title>Statistical analysis</title><p>The effects of different treatment arms on gametocytaemia were determined using per protocol analysis. The Chi square test (Chi) was used to compare proportions, and the non-parametric Wilcoxon-Mann-Whitney test (WMW) to compare metric or ordinal data. In order to use the closed testing procedure for multiple testing adjustment when comparing three groups, a global test is needed which compares three groups for differences. This is done by an exact chisquare test which is also valid for small sample sizes. When possible, estimates and the corresponding 95&#x00025; confidence interval are given. Calculations were performed with the program SAS release 9.1 (SAS&#x000ae; Institute Inc, Cary, NC, USA). Multiple testing between single arms in a three-armed trial is handeled by the closed testing procedure: If a difference between all three arms is assessed by a global test on significance level 5&#x00025;, it is possible to use the same level for the three two group comparisons. This procedure keeps the family wise error rate.</p></sec><sec id="s2d"><title>Ethical aspects</title><p>The study protocol was approved by the Ethics Committee of the Medical Faculty at Heidelberg University and the local Ethics Committee of Burkina Faso.</p></sec></sec><sec id="s3"><title>Results</title><p>One hundred and eighty children (61 MB-AS, 58 MB-AQ, 61 AS-AQ) were included in the study (<xref ref-type="fig" rid="pone-0005318-g001">Figure 1</xref>). There was only one loss to follow-up. Patients' demographical, clinical and parasitological characteristics at baseline did not differ between study groups, except for a small difference in weight (p&#x0200a;=&#x0200a;0.039; <xref ref-type="table" rid="pone-0005318-t001">Table 1</xref>). In particular, CQ pre-treatment, parasite density, and gametocyte carrier rate did not differ significantly between the treatment groups, although the latter tended to be increased in children receiving AQ-AS (<xref ref-type="table" rid="pone-0005318-t002">Table 2</xref>). Efficacy data of the study drugs have been published elsewhere. Briefly, PCR-corrected rates of adequate clinical and parasitological response at day 28 of follow-up were 62&#x00025; for MB-AS, 82&#x00025; for AS-AQ and 95&#x00025; for MB-AQ <xref rid="pone.0005318-Zoungrana1" ref-type="bibr">[25]</xref>.</p><fig id="pone-0005318-g001" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0005318.g001</object-id><label>Figure 1</label><caption><title>Flow chart of study patients.</title></caption><graphic xlink:href="pone.0005318.g001"/></fig><table-wrap id="pone-0005318-t001" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0005318.t001</object-id><label>Table 1</label><caption><title>Characteristics of study children at enrolment.</title></caption><alternatives><graphic id="pone-0005318-t001-1" xlink:href="pone.0005318.t001"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1">Characteristic</td><td align="left" rowspan="1" colspan="1">MB-AS group (n&#x0200a;=&#x0200a;61)</td><td align="left" rowspan="1" colspan="1">MB-AQ group (n&#x0200a;=&#x0200a;58)</td><td align="left" rowspan="1" colspan="1">AS-AQ group (n&#x0200a;=&#x0200a;61)</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Female sex (&#x00025;)</td><td align="left" rowspan="1" colspan="1">30 (49)</td><td align="left" rowspan="1" colspan="1">32 (55)</td><td align="left" rowspan="1" colspan="1">22 (36)</td></tr><tr><td align="left" rowspan="1" colspan="1">Median age in years (range)</td><td align="left" rowspan="1" colspan="1">7 (6&#x02013;10)</td><td align="left" rowspan="1" colspan="1">6 (6&#x02013;10)</td><td align="left" rowspan="1" colspan="1">7 (6&#x02013;10)</td></tr><tr><td align="left" rowspan="1" colspan="1">Median weight in kg (range)</td><td align="left" rowspan="1" colspan="1">20 (14&#x02013;32)<xref ref-type="table-fn" rid="nt101">&#x0002a;</xref>
</td><td align="left" rowspan="1" colspan="1">19 (13&#x02013;38)<xref ref-type="table-fn" rid="nt101">&#x0002a;</xref>
</td><td align="left" rowspan="1" colspan="1">19 (13&#x02013;33)<xref ref-type="table-fn" rid="nt101">&#x0002a;</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Median haematocrit in &#x00025; (range)</td><td align="left" rowspan="1" colspan="1">34 (26&#x02013;44)</td><td align="left" rowspan="1" colspan="1">36 (26&#x02013;42)</td><td align="left" rowspan="1" colspan="1">34 (24&#x02013;40)</td></tr><tr><td align="left" rowspan="1" colspan="1">Median number of <italic>P. falciparum</italic> trophozoites/&#x000b5;l (range)</td><td align="left" rowspan="1" colspan="1">33,000 (1,000&#x02013;265,050)</td><td align="left" rowspan="1" colspan="1">28,700 (1,000&#x02013;200,000)</td><td align="left" rowspan="1" colspan="1">31,000 (1,000&#x02013;258,000)</td></tr><tr><td align="left" rowspan="1" colspan="1">Prevalence of <italic>P. falciparum</italic> gametocytes (&#x00025;)</td><td align="left" rowspan="1" colspan="1">9 (15)</td><td align="left" rowspan="1" colspan="1">7 (12)</td><td align="left" rowspan="1" colspan="1">15 (25)</td></tr><tr><td align="left" rowspan="1" colspan="1">Median number of <italic>P. falciparum</italic> gametocytes/&#x000b5;l (range)</td><td align="left" rowspan="1" colspan="1">120 (80&#x02013;160)</td><td align="left" rowspan="1" colspan="1">200 (40&#x02013;320)</td><td align="left" rowspan="1" colspan="1">80 (40&#x02013;1,280)</td></tr><tr><td align="left" rowspan="1" colspan="1">Median duration of the current disease episode in days (range)</td><td align="left" rowspan="1" colspan="1">2 (1&#x02013;7)</td><td align="left" rowspan="1" colspan="1">2 (1&#x02013;7)</td><td align="left" rowspan="1" colspan="1">2 (1&#x02013;7)</td></tr><tr><td align="left" rowspan="1" colspan="1">Reported CQ treatment of current disease episode (&#x00025;)</td><td align="left" rowspan="1" colspan="1">6 (10)</td><td align="left" rowspan="1" colspan="1">12 (21)</td><td align="left" rowspan="1" colspan="1">10 (16)</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="nt101"><label>&#x0002a;</label><p>There was a small but significant difference in weight between the study groups (p&#x0200a;=&#x0200a;0.039).</p></fn></table-wrap-foot></table-wrap><table-wrap id="pone-0005318-t002" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0005318.t002</object-id><label>Table 2</label><caption><title>Efficacy of the study regimens against <italic>P. falciparum</italic> gametocytaemia.</title></caption><alternatives><graphic id="pone-0005318-t002-2" xlink:href="pone.0005318.t002"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">p-values</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">MB-AS group N&#x0200a;=&#x0200a;61</td><td align="left" rowspan="1" colspan="1">MB-AQ group N&#x0200a;=&#x0200a;58</td><td align="left" rowspan="1" colspan="1">AS-AQ group N&#x0200a;=&#x0200a;61</td><td align="left" rowspan="1" colspan="1">global</td><td align="left" rowspan="1" colspan="1">MB-AS vs. MB-AQ</td><td align="left" rowspan="1" colspan="1">MB-AS vs. AS-AQ</td><td align="left" rowspan="1" colspan="1">MB-AQ vs. AS-AQ</td></tr></thead><tbody><tr><td colspan="8" align="left" rowspan="1">Day 0</td></tr><tr><td align="left" rowspan="1" colspan="1">- Prevalence (95&#x00025; CI)</td><td align="left" rowspan="1" colspan="1">9 (14.8&#x00025; [7&#x00025;; 26&#x00025;])</td><td align="left" rowspan="1" colspan="1">7 (12.1&#x00025; [4&#x00025;; 20&#x00025;])</td><td align="left" rowspan="1" colspan="1">15 (24.6&#x00025; [14&#x00025;; 37&#x00025;])</td><td align="left" rowspan="1" colspan="1">0.168</td><td align="left" rowspan="1" colspan="1">0.790</td><td align="left" rowspan="1" colspan="1">0.255</td><td align="left" rowspan="1" colspan="1">0.100</td></tr><tr><td align="left" rowspan="1" colspan="1">- Median density (range)</td><td align="left" rowspan="1" colspan="1">120.0 (80.0&#x02013;160.0)</td><td align="left" rowspan="1" colspan="1">200.0 (40.0&#x02013;320.0)</td><td align="left" rowspan="1" colspan="1">80.0 (40.0&#x02013;1280.0)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td colspan="8" align="left" rowspan="1">Day 2</td></tr><tr><td align="left" rowspan="1" colspan="1">- Prevalence (95&#x00025; CI)</td><td align="left" rowspan="1" colspan="1">4 (6.6&#x00025; [2&#x00025;; 16&#x00025;])</td><td align="left" rowspan="1" colspan="1">7 (12.1&#x00025; [5&#x00025;; 23&#x00025;])</td><td align="left" rowspan="1" colspan="1">9 (14.8&#x00025; [7&#x00025;; 26&#x00025;])</td><td align="left" rowspan="1" colspan="1">0.350</td><td align="left" rowspan="1" colspan="1">0.355</td><td align="left" rowspan="1" colspan="1">0.240</td><td align="left" rowspan="1" colspan="1">0.790</td></tr><tr><td align="left" rowspan="1" colspan="1">- Median density (range)</td><td align="left" rowspan="1" colspan="1">100.0 (80.0&#x02013;200.0)</td><td align="left" rowspan="1" colspan="1">120.0 (80.0&#x02013;480.0)</td><td align="left" rowspan="1" colspan="1">160.0 (80.0&#x02013;1200.0)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td colspan="8" align="left" rowspan="1">Day 3</td></tr><tr><td align="left" rowspan="1" colspan="1">- Prevalence (95&#x00025; CI)</td><td align="left" rowspan="1" colspan="1">2 (3.3&#x00025;, [1&#x00025;; 11&#x00025;])</td><td align="left" rowspan="1" colspan="1">0 [0&#x00025;; 6&#x00025;]</td><td align="left" rowspan="1" colspan="1">9 (14.8&#x00025; [7&#x00025;; 26&#x00025;])</td><td align="left" rowspan="1" colspan="1">0.002</td><td align="left" rowspan="1" colspan="1">0.496</td><td align="left" rowspan="1" colspan="1">0.054</td><td align="left" rowspan="1" colspan="1">0.003</td></tr><tr><td align="left" rowspan="1" colspan="1">- Median density (range)</td><td align="left" rowspan="1" colspan="1">80.0 (40.0&#x02013;120.0)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">160.0 (40.0&#x02013;440.0)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td colspan="8" align="left" rowspan="1">Day 7</td></tr><tr><td align="left" rowspan="1" colspan="1">- Prevalence (95&#x00025; CI)</td><td align="left" rowspan="1" colspan="1">0 [0&#x00025;; 6&#x00025;]</td><td align="left" rowspan="1" colspan="1">0 [0&#x00025;; 6&#x00025;]</td><td align="left" rowspan="1" colspan="1">11 (18.0&#x00025; [9&#x00025;; 30&#x00025;])</td><td align="left" rowspan="1" colspan="1">&#x0003c;.001</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">&#x0003c;.001</td><td align="left" rowspan="1" colspan="1">&#x0003c;.001</td></tr><tr><td align="left" rowspan="1" colspan="1">- Median density (range)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">120.0 (80.0&#x02013;480.0)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">- missing<xref ref-type="table-fn" rid="nt102">&#x0002a;</xref>
</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td colspan="8" align="left" rowspan="1">Day 14</td></tr><tr><td align="left" rowspan="1" colspan="1">- Prevalence (95&#x00025; CI)</td><td align="left" rowspan="1" colspan="1">0 [0&#x00025;; 6&#x00025;]</td><td align="left" rowspan="1" colspan="1">0 [0&#x00025;; 6&#x00025;]</td><td align="left" rowspan="1" colspan="1">4 (6.8&#x00025; [2&#x00025;; 16&#x00025;])</td><td align="left" rowspan="1" colspan="1">0.035</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.119</td><td align="left" rowspan="1" colspan="1">0.110</td></tr><tr><td align="left" rowspan="1" colspan="1">- Median density (range)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">180.0 (160.0&#x02013;400.0)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">- missing<xref ref-type="table-fn" rid="nt102">&#x0002a;</xref>
</td><td align="left" rowspan="1" colspan="1">3</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr></tbody></table></alternatives><table-wrap-foot><fn id="nt102"><label>&#x0002a;</label><p>Patients not available for blood test on respective study days.</p></fn></table-wrap-foot></table-wrap><p>The prevalence of gametocytes declined following treatment, regardless of the drug administered. However, both MB-AS and MB-AQ were significantly more effective in this regard than AS-AQ during follow-up (<xref ref-type="table" rid="pone-0005318-t002">Table 2</xref>). No gametoctyes were detected one or two weeks following treatment with the MB-containing regimes whereas their respective prevalences were 18&#x00025; and 7&#x00025; in AS-AQ treated children.</p><p>Similar findings were observed among patients who exhibited gametocytaemia at enrolment (<xref ref-type="table" rid="pone-0005318-t003">Table 3</xref>).</p><table-wrap id="pone-0005318-t003" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0005318.t003</object-id><label>Table 3</label><caption><title>
<italic>P. falciparum</italic> gametocytaemia during follow-up in patients with <italic>P. falciparum</italic> gametocytaemia on day 0.</title></caption><alternatives><graphic id="pone-0005318-t003-3" xlink:href="pone.0005318.t003"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">p-values</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">MB-AS group N&#x0200a;=&#x0200a;9</td><td align="left" rowspan="1" colspan="1">MB-AQ group N&#x0200a;=&#x0200a;7</td><td align="left" rowspan="1" colspan="1">AS-AQ group N&#x0200a;=&#x0200a;15</td><td align="left" rowspan="1" colspan="1">global</td><td align="left" rowspan="1" colspan="1">MB-AS vs. MB-AQ</td><td align="left" rowspan="1" colspan="1">MB-AS vs. AS-AQ</td><td align="left" rowspan="1" colspan="1">MB-AQ vs. AS-AQ</td></tr></thead><tbody><tr><td colspan="8" align="left" rowspan="1">Day 2</td></tr><tr><td align="left" rowspan="1" colspan="1">- Prevalence (95&#x00025; CI)</td><td align="left" rowspan="1" colspan="1">2 (22.2&#x00025; [3&#x00025;; 60&#x00025;])</td><td align="left" rowspan="1" colspan="1">1 (14.3&#x00025; [1&#x00025;; 66&#x00025;])</td><td align="left" rowspan="1" colspan="1">8 (53.3&#x00025; [27&#x00025;; 79&#x00025;])</td><td align="left" rowspan="1" colspan="1">0.142</td><td align="left" rowspan="1" colspan="1">1.000</td><td align="left" rowspan="1" colspan="1">0.210</td><td align="left" rowspan="1" colspan="1">0.165</td></tr><tr><td align="left" rowspan="1" colspan="1">- Median density (range)</td><td align="left" rowspan="1" colspan="1">100.0 (80.0&#x02013;120.0)</td><td align="left" rowspan="1" colspan="1">480.0 (480.0&#x02013;480.0)</td><td align="left" rowspan="1" colspan="1">220.0 (80.0&#x02013;1200.0)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td colspan="8" align="left" rowspan="1">Day 3</td></tr><tr><td align="left" rowspan="1" colspan="1">- Prevalence (95&#x00025; CI)</td><td align="left" rowspan="1" colspan="1">0 [0&#x00025;; 34&#x00025;]</td><td align="left" rowspan="1" colspan="1">0 [0&#x00025;; 41&#x00025;]</td><td align="left" rowspan="1" colspan="1">5 (33.3&#x00025; [12&#x00025;; 62&#x00025;])</td><td align="left" rowspan="1" colspan="1">0.047</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.118</td><td align="left" rowspan="1" colspan="1">0.135</td></tr><tr><td align="left" rowspan="1" colspan="1">- Median density (range)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">200.0 (160.0&#x02013;440.0)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td colspan="8" align="left" rowspan="1">Day 7</td></tr><tr><td align="left" rowspan="1" colspan="1">- Prevalence (95&#x00025; CI)</td><td align="left" rowspan="1" colspan="1">0 [0&#x00025;; 34&#x00025;]</td><td align="left" rowspan="1" colspan="1">0 [0&#x00025;; 41&#x00025;]</td><td align="left" rowspan="1" colspan="1">6 (40.0&#x00025; [16&#x00025;; 68&#x00025;])</td><td align="left" rowspan="1" colspan="1">0.024</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.052</td><td align="left" rowspan="1" colspan="1">0.121</td></tr><tr><td align="left" rowspan="1" colspan="1">- Median density (range)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">300.0 (80.0&#x02013;480.0)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td colspan="8" align="left" rowspan="1">Day 14</td></tr><tr><td align="left" rowspan="1" colspan="1">- Prevalence (95&#x00025; CI)</td><td align="left" rowspan="1" colspan="1">0 [0&#x00025;; 34&#x00025;]</td><td align="left" rowspan="1" colspan="1">0 [0&#x00025;; 41&#x00025;]</td><td align="left" rowspan="1" colspan="1">4 (26.7&#x00025; [8&#x00025;; 55&#x00025;])</td><td align="left" rowspan="1" colspan="1">0.134</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.259</td><td align="left" rowspan="1" colspan="1">0.263</td></tr><tr><td align="left" rowspan="1" colspan="1">- Median density (range)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">180.0 (160.0&#x02013;400.0)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr></tbody></table></alternatives></table-wrap><p>Excluding patients with <italic>P. falciparum</italic> gametocytes on day 0 and/or day 2, both MB-based treatment regimes yielded lower <italic>P. falciparum</italic> gametocyte prevalence on day 3 and day 7 compared to AS-AQ (<xref ref-type="table" rid="pone-0005318-t004">Table 4</xref>). On day 14, no gametocytes were detected in all study groups.</p><table-wrap id="pone-0005318-t004" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0005318.t004</object-id><label>Table 4</label><caption><title>Efficacy of the study drugs against <italic>P. falciparum</italic> gametocytaemia after exclusion of all cases with gametocytes on day 0 and/or day 2.</title></caption><alternatives><graphic id="pone-0005318-t004-4" xlink:href="pone.0005318.t004"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">p-values</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">MB-AS group N&#x0200a;=&#x0200a;50</td><td align="left" rowspan="1" colspan="1">MB-AQ group N&#x0200a;=&#x0200a;45</td><td align="left" rowspan="1" colspan="1">AS-AQ group N&#x0200a;=&#x0200a;45</td><td align="left" rowspan="1" colspan="1">global</td><td align="left" rowspan="1" colspan="1">MB-AS vs. MB-AQ</td><td align="left" rowspan="1" colspan="1">MB-AS vs. AS-AQ</td><td align="left" rowspan="1" colspan="1">MB-AQ vs. AS-AQ</td></tr></thead><tbody><tr><td colspan="8" align="left" rowspan="1">Day 3</td></tr><tr><td align="left" rowspan="1" colspan="1">- Prevalence</td><td align="left" rowspan="1" colspan="1">1 (2.0&#x00025; [1&#x00025;;11&#x00025;])</td><td align="left" rowspan="1" colspan="1">0 [0&#x00025;; 8&#x00025;]</td><td align="left" rowspan="1" colspan="1">4 (8.9&#x00025; [2&#x00025;; 21&#x00025;])</td><td align="left" rowspan="1" colspan="1">0.079</td><td align="left" rowspan="1" colspan="1">1.000</td><td align="left" rowspan="1" colspan="1">0.186</td><td align="left" rowspan="1" colspan="1">0.117</td></tr><tr><td align="left" rowspan="1" colspan="1">- Median density (range)</td><td align="left" rowspan="1" colspan="1">120.0 (120.0&#x02013;120.0)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">60.0 (40.0&#x02013;120.0)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td colspan="8" align="left" rowspan="1">Day 7</td></tr><tr><td align="left" rowspan="1" colspan="1">- Prevalence</td><td align="left" rowspan="1" colspan="1">0 [0&#x00025;; 7&#x00025;]</td><td align="left" rowspan="1" colspan="1">0 [0&#x00025;; 8&#x00025;]</td><td align="left" rowspan="1" colspan="1">4 (8.9&#x00025; [2&#x00025;; 21&#x00025;])</td><td align="left" rowspan="1" colspan="1">0.020</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.049</td><td align="left" rowspan="1" colspan="1">0.117</td></tr><tr><td align="left" rowspan="1" colspan="1">- Median density (range)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">100.0 (80.0&#x02013;120.0)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">- missing<xref ref-type="table-fn" rid="nt103">&#x0002a;</xref>
</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td colspan="8" align="left" rowspan="1">Day 14</td></tr><tr><td align="left" rowspan="1" colspan="1">- Prevalence</td><td align="left" rowspan="1" colspan="1">0 [0&#x00025;; 8&#x00025;]</td><td align="left" rowspan="1" colspan="1">0 [0&#x00025;; 8&#x00025;]</td><td align="left" rowspan="1" colspan="1">0 [0&#x00025;; 8&#x00025;]</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">- Median density (range)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">- missing<xref ref-type="table-fn" rid="nt103">&#x0002a;</xref>
</td><td align="left" rowspan="1" colspan="1">3</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr></tbody></table></alternatives><table-wrap-foot><fn id="nt103"><label>&#x0002a;</label><p>Patients not available for blood test on respective study days.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s4"><title>Discussion</title><p>Treatment of malaria with MB-based regimens not only is more effective than AQ-AS in this part of Burkina Faso <xref rid="pone.0005318-Zoungrana1" ref-type="bibr">[25]</xref> but also associated with a markedly reduced prevalence of <italic>P. falciparum</italic> gametocytaemia following treatment. In this first respective study, the gametocytocidal effect of MB-combination treatment significantly exceeded that of AQ-AS. In fact, when following only those subjects who had gametocytaemia at baseline, <italic>P. falciparum</italic> gametocytes were detected exclusively in the ACT control group. In children presenting without gametocytes, the finding of a lower <italic>P. falciparum</italic> gametocytaemia during follow-up in both MB-based combinations remained but was no longer that marked. These results point to a broad activity of MB against both, already existing (older) gametocytes and newly developing (younger) ones. However, due to the limited sample size these observations are based on small and not always statistically significant numbers and need to be interpreted with some caution. Moreover, <italic>P. falciparum</italic> gametocytaemia was not included as a specific endpoint <italic>a priori</italic>. This does not change the reliability of our findings as all slides from the trial were safely stored in the CRSN laboratory and re-examined by blinded laboratory technicians. Measuring the effects of the different treatments on submicroscopic gametocytaemia could have been another option to increase the power of this study. For instance, in a recent trial in Tanzanian children, gametocytes were detected in 23&#x00025; and 89&#x00025; by microscopy and real-time PCR assays, respectively <xref rid="pone.0005318-Shekalaghe1" ref-type="bibr">[32]</xref>, and data from The Gambia and Kenya indicate the transmission potential of submicroscopic gametocytaemia <xref rid="pone.0005318-Okell1" ref-type="bibr">[33]</xref>. However, standardised collection of appropriate samples to address this issue was not performed in the present study.</p><p>ACT has been shown to be highly effective against <italic>P. falciparum</italic> gametocytes except on the more mature stages of their development <xref rid="pone.0005318-Adjuik1" ref-type="bibr">[3]</xref>, <xref rid="pone.0005318-Okell1" ref-type="bibr">[33]</xref>. This is supported by our finding of a rather low respective efficacy among patients harbouring gametocytes at baseline. MB-based combinations not only cleared all pre-existing gametocytes but appeared to have a stronger effect than AQ-AS on the emergence of young gametocytes following treatment. This points to the possibility of a synergistic use of MB and artemisinin derivatives against gametocytes. Unfortunately, the small sample size of the present study did not allow probing this hypothesis.</p><p>The mechanism by which MB acts against gametocytes is obscure so far. Rapid elimination of asexual parasites (including fractions committed to gametocytogenesis) by MB-based combination treatment may be involved in preventing subsequent gametocytaemia. However, MB-AQ exhibited superior gametocytocidal effects but slower clearance of asexual parasites as compared to AQ-AS <xref rid="pone.0005318-Zoungrana1" ref-type="bibr">[25]</xref>. Interestingly, the remarkable effect of low doses of a MB derivative, plasmoquine, on <italic>P. falciparum</italic> gametocytes has long been known. In Sudanese children in the early 1930s, plasmoquine given prophylactically at a dosage of 0.02 mg/kg twice weekly, i.e. at a fraction of the therapeutical dose, almost completely prevented the occurrence of gametocytes <xref rid="pone.0005318-Henderson1" ref-type="bibr">[34]</xref>. Similarly, plasmoquine chemoprophylaxis taken twice a week yielded a substantial reduction of infected mosquitos in rubber plantation camps in Liberia in 1931 which was attributed to the drug's impact on gametocyte carriage <xref rid="pone.0005318-Barber1" ref-type="bibr">[35]</xref>. Eventually, the potential of plasmoquine to interrupt transmission was recognized and recommended for this purpose <xref rid="pone.0005318-Anonymous1" ref-type="bibr">[36]</xref>. The successor of plasmoquine, and structurally closely related, is primaquine. Primaquine not only is the drug of choice to eliminate hypnozoites in vivax or ovale malaria. Also, in experimental infections, the drug distinctly reduced the number of circulating gametocytes and sterilised those remaining <xref rid="pone.0005318-Rieckmann1" ref-type="bibr">[37]</xref>. In a recent trial in Tanzania, single dose primaquine given on the third day of treatment with sulfadoxine-pyrimethamine (SP) <italic>plus</italic> AS reduced gametocyte carriage by more than 80&#x00025; as compared to SP-AS alone <xref rid="pone.0005318-Shekalaghe1" ref-type="bibr">[32]</xref>. However, asexual blood stages of <italic>P. falciparum</italic> are not affected by therapeutical doses of primaquine, and a reduced gametocytocidal activity has been reported from India <xref rid="pone.0005318-Arnold1" ref-type="bibr">[38]</xref>, <xref rid="pone.0005318-Gogtay1" ref-type="bibr">[39]</xref>. It might be premature to consider MB as an alternative to primaquine as an adjunct to <italic>P. falciparum</italic> treatment, intended to block post-treatment transmission. Yet, MB shows promising features in this regard including strong activity against asexual parasites, developing and mature gametocytes, as well as synergism with artemisinine derivatives <xref rid="pone.0005318-Zoungrana1" ref-type="bibr">[25]</xref>, <xref rid="pone.0005318-Okell1" ref-type="bibr">[33]</xref>. Possibly, and in analogy to plasmoquine, MB exerts its gametocytocidal effects at dosages below those used in treatment which might be beneficial in terms of dosing and tolerability. Taken together, these features warrant further investigations of MB as a partner compound in ACT and non-ACT combinations as well as in blocking transmission. In this regard, studies on the infectivity of gametocytes from MB-treated individuals are needed.</p><p>In summary, this study provides evidence that suggests a high efficacy of MB-based combination therapy against <italic>P. falciparum</italic> gametocytes. A combination of MB with an artemisinin derivate may thus maximise the gametocytocidal effects of the latter. These findings add to already existing <italic>in vitro</italic> and <italic>in vivo</italic> evidence of a synergy between MB and artemisinins <xref rid="pone.0005318-Zoungrana1" ref-type="bibr">[25]</xref>, <xref rid="pone.0005318-Akoachere1" ref-type="bibr">[40]</xref>. If such findings would be confirmed in larger studies and considering the impending advent of artemisinin resistance <xref rid="pone.0005318-Duffy1" ref-type="bibr">[16]</xref>&#x02013;<xref rid="pone.0005318-Noedl1" ref-type="bibr">[18]</xref>, including MB in ACT schemes would be an interesting option to improve treatment efficacy, prevent the development of resistance, and to reduce the transmission of (resistant) <italic>P. falciparum</italic> parasites.</p></sec><sec sec-type="supplementary-material" id="s5"><title>Supporting Information</title><supplementary-material content-type="local-data" id="pone.0005318.s001"><label>Checklist S1</label><caption><p>CONSORT Checklist</p><p>(0.06 MB DOC)</p></caption><media xlink:href="pone.0005318.s001.doc"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0005318.s002"><label>Protocol S1</label><caption><p>Trial Protocol</p><p>(0.20 MB DOC)</p></caption><media xlink:href="pone.0005318.s002.doc"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><fn-group><fn fn-type="COI-statement"><p><bold>Competing Interests: </bold>The authors have declared that no competing interests exist.</p></fn><fn fn-type="financial-disclosure"><p><bold>Funding: </bold>The study was funded by grants of the Deutsche Forschungsgemeinschaft (SFB 544 &#x0201c;Control of Tropical Infectious Diseases&#x0201d; at the Ruprecht-Karls-University Heidelberg and Schi 102/9-3). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</p></fn></fn-group><ref-list><title>References</title><ref id="pone.0005318-Greenwood1"><label>1</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Greenwood</surname><given-names>BM</given-names></name><name><surname>Bojang</surname><given-names>K</given-names></name><name><surname>Whitty</surname><given-names>JM</given-names></name><name><surname>Targett</surname><given-names>GA</given-names></name></person-group>
<year>2005</year>
<article-title>Malaria.</article-title>
<source>Lancet</source>
<volume>365</volume>
<fpage>1487</fpage>
<lpage>98</lpage>
<pub-id pub-id-type="pmid">15850634</pub-id></element-citation></ref><ref id="pone.0005318-Lengeler1"><label>2</label><element-citation publication-type="book">
<person-group person-group-type="author"><name><surname>Lengeler</surname><given-names>C</given-names></name></person-group>
<collab>Insecticide treated bed nets and curtains for preventing malaria (Cochrane Review)</collab>
<year>2004</year>
<source>The Cochrane Library</source>
<publisher-loc>Oxford</publisher-loc>
<publisher-name>Update Software</publisher-name>
</element-citation></ref><ref id="pone.0005318-Adjuik1"><label>3</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Adjuik</surname><given-names>M</given-names></name><name><surname>Babiker</surname><given-names>A</given-names></name><name><surname>Garner</surname><given-names>P</given-names></name><name><surname>Olliario</surname><given-names>P</given-names></name><name><surname>Taylor</surname><given-names>W</given-names></name><name><surname>White</surname><given-names>N</given-names></name></person-group>
<year>2004</year>
<article-title>Artesunate combinations for treatment of malaria: meta-analysis.</article-title>
<source>Lancet</source>
<volume>363</volume>
<fpage>9</fpage>
<lpage>17</lpage>
<pub-id pub-id-type="pmid">14723987</pub-id></element-citation></ref><ref id="pone.0005318-Aponte1"><label>4</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Aponte</surname><given-names>JJ</given-names></name><name><surname>Aide</surname><given-names>P</given-names></name><name><surname>Renom</surname><given-names>M</given-names></name><name><surname>Mandomando</surname><given-names>I</given-names></name><name><surname>Basset</surname><given-names>Q</given-names></name><etal/></person-group>
<year>2007</year>
<article-title>Safety of the RTS,S/AS02D candidate malaria vaccine in infants living in a highly endemic area of Mazambique: a double blind randomised controlled phase I/IIb trial.</article-title>
<source>Lancet</source>
<volume>370</volume>
<fpage>1543</fpage>
<lpage>51</lpage>
<pub-id pub-id-type="pmid">17949807</pub-id></element-citation></ref><ref id="pone.0005318-Sachs1"><label>5</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sachs</surname><given-names>JD</given-names></name></person-group>
<year>2005</year>
<article-title>Achieving the millenium development goals &#x02013; the case of malaria.</article-title>
<source>N Engl J Med</source>
<volume>352</volume>
<fpage>115</fpage>
<lpage>17</lpage>
<pub-id pub-id-type="pmid">15647571</pub-id></element-citation></ref><ref id="pone.0005318-White1"><label>6</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>White</surname><given-names>NJ</given-names></name></person-group>
<year>2006</year>
<article-title>Malaria &#x02013; time to act.</article-title>
<source>N Engl J Med</source>
<volume>355</volume>
<fpage>1956</fpage>
<lpage>57</lpage>
<pub-id pub-id-type="pmid">17093246</pub-id></element-citation></ref><ref id="pone.0005318-Feachem1"><label>7</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Feachem</surname><given-names>RGA</given-names></name><name><surname>Sabot</surname><given-names>OJ</given-names></name></person-group>
<year>2007</year>
<article-title>Global malaria control in the 21st century &#x02013; a historic but fleeting opportunity.</article-title>
<source>JAMA</source>
<volume>297</volume>
<fpage>2281</fpage>
<lpage>84</lpage>
<pub-id pub-id-type="pmid">17519417</pub-id></element-citation></ref><ref id="pone.0005318-Tanner1"><label>8</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Tanner</surname><given-names>M</given-names></name><name><surname>de Savigny</surname><given-names>D</given-names></name></person-group>
<year>2008</year>
<article-title>Malaria eradication back on the table.</article-title>
<source>Bull WHO</source>
<volume>86</volume>
<fpage>82</fpage>
<lpage>83</lpage>
<pub-id pub-id-type="pmid">18297155</pub-id></element-citation></ref><ref id="pone.0005318-Fegan1"><label>9</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Fegan</surname><given-names>GW</given-names></name><name><surname>Noor</surname><given-names>AM</given-names></name><name><surname>Akhwale</surname><given-names>WS</given-names></name><name><surname>Cousens</surname><given-names>S</given-names></name><name><surname>Snow</surname><given-names>RW</given-names></name></person-group>
<year>2007</year>
<article-title>Effect of expanded insecticide-treated bednet coverage on child survival in rural Kenya: a longitudinal study.</article-title>
<source>Lancet</source>
<volume>370</volume>
<fpage>1035</fpage>
<lpage>39</lpage>
<pub-id pub-id-type="pmid">17889242</pub-id></element-citation></ref><ref id="pone.0005318-Bhattarai1"><label>10</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bhattarai</surname><given-names>A</given-names></name><name><surname>Ali</surname><given-names>AS</given-names></name><name><surname>Kachur</surname><given-names>P</given-names></name><name><surname>Martensson</surname><given-names>A</given-names></name><name><surname>Abbas</surname><given-names>AK</given-names></name><etal/></person-group>
<year>2007</year>
<article-title>Impact of artemisinin-based combination therapy and insecticide-treated nets on malaria burden in Zanzibar.</article-title>
<source>PLoS Med</source>
<volume>4</volume>
<fpage>3309</fpage>
</element-citation></ref><ref id="pone.0005318-Samarasekera1"><label>11</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Samarasekera</surname><given-names>U</given-names></name></person-group>
<year>2008</year>
<article-title>Drug subsidy could help Tanzania tackle malaria.</article-title>
<source>Lancet</source>
<volume>371</volume>
<fpage>1403</fpage>
<lpage>06</lpage>
<pub-id pub-id-type="pmid">18446925</pub-id></element-citation></ref><ref id="pone.0005318-Price1"><label>12</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Price</surname><given-names>R</given-names></name><name><surname>Nosten</surname><given-names>F</given-names></name><name><surname>Luxemburger</surname><given-names>C</given-names></name><name><surname>Kuile</surname><given-names>FOT</given-names></name><name><surname>Paiphun</surname><given-names>L</given-names></name><etal/></person-group>
<year>1996</year>
<article-title>Effects of artemisinin derivates on malaria transmissibility.</article-title>
<source>Lancet</source>
<volume>347</volume>
<fpage>1654</fpage>
<lpage>58</lpage>
<pub-id pub-id-type="pmid">8642959</pub-id></element-citation></ref><ref id="pone.0005318-Sutherland1"><label>13</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sutherland</surname><given-names>CJ</given-names></name><name><surname>Ord</surname><given-names>R</given-names></name><name><surname>Dunyo</surname><given-names>S</given-names></name><name><surname>Jawara</surname><given-names>M</given-names></name><name><surname>Drakeley</surname><given-names>CJ</given-names></name><etal/></person-group>
<year>2005</year>
<article-title>Reduction of malaria transmission to Anopheles mosquitoes with a six-dose regimen of Co-Arthemeter.</article-title>
<source>PLoS Med</source>
<volume>2</volume>
<fpage>e92</fpage>
<pub-id pub-id-type="pmid">15839740</pub-id></element-citation></ref><ref id="pone.0005318-Garner1"><label>14</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Garner</surname><given-names>P</given-names></name><name><surname>Graves</surname><given-names>PM</given-names></name></person-group>
<year>2005</year>
<article-title>The benefits of artemisinin combination therapy for malaria extend beyond the individual patient.</article-title>
<source>PLoS Med</source>
<volume>2(4)</volume>
<fpage>e105</fpage>
<pub-id pub-id-type="pmid">15839750</pub-id></element-citation></ref><ref id="pone.0005318-Targett1"><label>15</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Targett</surname><given-names>G</given-names></name><name><surname>Drakeley</surname><given-names>C</given-names></name><name><surname>Jawara</surname><given-names>M</given-names></name><name><surname>von Seidlein</surname><given-names>L</given-names></name><name><surname>Colemen</surname><given-names>R</given-names></name><etal/></person-group>
<year>2001</year>
<article-title>Artesunate reduces but does not prevent posttreatment transmission of <italic>Plasmodium falciparum</italic> to Anopheles gambiae.</article-title>
<source>J Infect Dis</source>
<volume>183</volume>
<fpage>1254</fpage>
<lpage>59</lpage>
<pub-id pub-id-type="pmid">11262208</pub-id></element-citation></ref><ref id="pone.0005318-Duffy1"><label>16</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Duffy</surname><given-names>PE</given-names></name><name><surname>Sibley</surname><given-names>CH</given-names></name></person-group>
<year>2005</year>
<article-title>Are we loosing artemisinin combination therapy already?</article-title>
<source>Lancet</source>
<volume>366</volume>
<fpage>1908</fpage>
<lpage>09</lpage>
<pub-id pub-id-type="pmid">16325683</pub-id></element-citation></ref><ref id="pone.0005318-Jambou1"><label>17</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Jambou</surname><given-names>R</given-names></name><name><surname>Legrand</surname><given-names>E</given-names></name><name><surname>Niang</surname><given-names>M</given-names></name><name><surname>Khim</surname><given-names>N</given-names></name><name><surname>Lim</surname><given-names>P</given-names></name><etal/></person-group>
<year>2005</year>
<article-title>Resistance of <italic>Plasmodium falciparum</italic> field isolates to in-vitro artemether and point mutations of the SERCA-type PfATPase6.</article-title>
<source>Lancet</source>
<volume>366</volume>
<fpage>1960</fpage>
<lpage>3</lpage>
<pub-id pub-id-type="pmid">16325698</pub-id></element-citation></ref><ref id="pone.0005318-Noedl1"><label>18</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Noedl</surname><given-names>H</given-names></name><name><surname>Chanthap</surname><given-names>L</given-names></name><name><surname>Se</surname><given-names>Y</given-names></name></person-group>
<year>2007</year>
<article-title>Artemisinin resistance in Cambodia.</article-title>
<source>Trop Med Int Health</source>
<volume>12</volume>
<issue>supplement</issue>
<fpage>69</fpage>
</element-citation></ref><ref id="pone.0005318-Guttmann1"><label>19</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Guttmann</surname><given-names>P</given-names></name><name><surname>Ehrlich</surname><given-names>P</given-names></name></person-group>
<year>1891</year>
<article-title>&#x000dc;ber die Wirkung des Methylenblau bei Malaria.</article-title>
<source>Berliner Klinische Wochenschrift</source>
<volume>39</volume>
<fpage>953</fpage>
<lpage>956</lpage>
</element-citation></ref><ref id="pone.0005318-Schirmer1"><label>20</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Schirmer</surname><given-names>RH</given-names></name><name><surname>Coulibaly</surname><given-names>B</given-names></name><name><surname>Stich</surname><given-names>A</given-names></name><name><surname>Scheiwein</surname><given-names>M</given-names></name><name><surname>Merkle</surname><given-names>H</given-names></name><etal/></person-group>
<year>2003</year>
<article-title>Methylene blue in the treatment of malaria &#x02013; past and presence.</article-title>
<source>Redox Report</source>
<volume>8</volume>
<fpage>272</fpage>
<lpage>76</lpage>
<pub-id pub-id-type="pmid">14962363</pub-id></element-citation></ref><ref id="pone.0005318-Buchholz1"><label>21</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Buchholz</surname><given-names>K</given-names></name><name><surname>Schirmer</surname><given-names>RH</given-names></name><name><surname>Eubel</surname><given-names>JK</given-names></name><name><surname>Akoach&#x000e8;re</surname><given-names>MB</given-names></name><name><surname>Dandekar</surname><given-names>T</given-names></name><etal/></person-group>
<year>2008</year>
<article-title>Interactions of methylene blue with human disulfide reductases and their orthologues from <italic>Plasmodium falciparum</italic>.</article-title>
<source>Antimicr Agents Chemother</source>
<volume>52</volume>
<fpage>183</fpage>
<lpage>91</lpage>
</element-citation></ref><ref id="pone.0005318-Mandi1"><label>22</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mandi</surname><given-names>G</given-names></name><name><surname>Witte</surname><given-names>S</given-names></name><name><surname>Meissner</surname><given-names>P</given-names></name><name><surname>Coulibaly</surname><given-names>B</given-names></name><name><surname>Mansmann</surname><given-names>U</given-names></name><etal/></person-group>
<year>2005</year>
<article-title>Safety of the combination of chloroquine and methylene blue in healthy adult men with G6PD deficiency from rural Burkina Faso.</article-title>
<source>Trop Med Int Health</source>
<volume>10</volume>
<fpage>32</fpage>
<lpage>38</lpage>
<pub-id pub-id-type="pmid">15655011</pub-id></element-citation></ref><ref id="pone.0005318-Meissner1"><label>23</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Meissner</surname><given-names>P</given-names></name><name><surname>Mandi</surname><given-names>G</given-names></name><name><surname>Witte</surname><given-names>S</given-names></name><name><surname>Coulibaly</surname><given-names>B</given-names></name><name><surname>Mansmann</surname><given-names>U</given-names></name><etal/></person-group>
<year>2005</year>
<article-title>Safety of the methylene blue plus chloroquine combination in the treatment of uncomplicated falciparum malaria in young children of Burkina Faso.</article-title>
<source>Malaria J</source>
<volume>4</volume>
<fpage>46</fpage>
</element-citation></ref><ref id="pone.0005318-Meissner2"><label>24</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Meissner</surname><given-names>P</given-names></name><name><surname>Mandi</surname><given-names>G</given-names></name><name><surname>Coulibaly</surname><given-names>B</given-names></name><name><surname>Witte</surname><given-names>S</given-names></name><name><surname>Tapsoba</surname><given-names>T</given-names></name><etal/></person-group>
<year>2006</year>
<article-title>Methylene blue for malaria in Africa: results from a dose-finding study in combination with chloroquine.</article-title>
<source>Malaria J</source>
<volume>5</volume>
<fpage>84</fpage>
</element-citation></ref><ref id="pone.0005318-Zoungrana1"><label>25</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zoungrana</surname><given-names>A</given-names></name><name><surname>Coulibaly</surname><given-names>B</given-names></name><name><surname>Si&#x000e9;</surname><given-names>A</given-names></name><name><surname>Walter-Sack</surname><given-names>I</given-names></name><name><surname>Mockenhaupt</surname><given-names>FP</given-names></name><etal/></person-group>
<year>2008</year>
<article-title>Safety and efficacy of methylene blue combined with artesunate or amodiaquine for uncomplicated falciparum malaria: a randomized controlled trial from Burkina Faso.</article-title>
<source>PLoS One</source>
<volume>3(2)</volume>
<fpage>e1630</fpage>
<pub-id pub-id-type="pmid">18286187</pub-id></element-citation></ref><ref id="pone.0005318-Greenwood2"><label>26</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Greenwood</surname><given-names>D</given-names></name></person-group>
<year>1995</year>
<article-title>Historical perspective. Conflicts of interest: the genesis of synthetic antimalarial agents in peace and war.</article-title>
<source>J Antimicrobial Chemotherapy</source>
<volume>36</volume>
<fpage>857</fpage>
<lpage>72</lpage>
</element-citation></ref><ref id="pone.0005318-Rawlings1"><label>27</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Rawlings</surname><given-names>DJ</given-names></name><name><surname>Fujioka</surname><given-names>H</given-names></name><name><surname>Fried</surname><given-names>M</given-names></name><name><surname>Keister</surname><given-names>DB</given-names></name><name><surname>Aikawa</surname><given-names>M</given-names></name><name><surname>Kaslow</surname><given-names>DC</given-names></name></person-group>
<year>1992</year>
<article-title>Alpha-tubulin II is a male-specific protein in <italic>Plasmodium falciparum</italic>.</article-title>
<source>Mol Biochem Parasitol</source>
<volume>56</volume>
<fpage>239</fpage>
<lpage>250</lpage>
<pub-id pub-id-type="pmid">1484548</pub-id></element-citation></ref><ref id="pone.0005318-Mller1"><label>28</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>M&#x000fc;ller</surname><given-names>O</given-names></name><name><surname>Traor&#x000e9;</surname><given-names>C</given-names></name><name><surname>Kouyat&#x000e9;</surname><given-names>B</given-names></name><name><surname>Becher</surname><given-names>H</given-names></name></person-group>
<year>2003</year>
<article-title>Malaria morbidity, treatment seeking behaviour, and mortality in a cohort of young children in rural Burkina Faso.</article-title>
<source>Trop Med Int Health</source>
<volume>8</volume>
<fpage>290</fpage>
<lpage>296</lpage>
<pub-id pub-id-type="pmid">12667146</pub-id></element-citation></ref><ref id="pone.0005318-Kouyat1"><label>29</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kouyat&#x000e9;</surname><given-names>B</given-names></name><name><surname>Si&#x000e9;</surname><given-names>A</given-names></name><name><surname>Y&#x000e9;</surname><given-names>M</given-names></name><name><surname>De Allegri</surname><given-names>M</given-names></name><name><surname>M&#x000fc;ller</surname><given-names>O</given-names></name></person-group>
<year>2007</year>
<article-title>The great failure of malaria control in Africa: a district perspective from Burkina Faso.</article-title>
<source>PLoS Med</source>
<volume>4</volume>
<fpage>e127</fpage>
<pub-id pub-id-type="pmid">17550300</pub-id></element-citation></ref><ref id="pone.0005318-WHO1"><label>30</label><element-citation publication-type="other">
<collab>WHO</collab>
<year>2003</year>
<article-title>Assessment and monitoring of antimalarial drug efficacy for the treatment of uncomplicated falciparum malaria.</article-title>
<comment>WHO/HTM/RBM/2003.50</comment>
</element-citation></ref><ref id="pone.0005318-Mller2"><label>31</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>M&#x000fc;ller</surname><given-names>O</given-names></name><name><surname>Becher</surname><given-names>H</given-names></name><name><surname>Baltussen</surname><given-names>A</given-names></name><name><surname>Ye</surname><given-names>Y</given-names></name><name><surname>Diallo</surname><given-names>D</given-names></name><etal/></person-group>
<year>2001</year>
<article-title>Effect of zinc supplementation on malaria morbidity among Westafrican children: a randomized double-blind placebo-controlled trial.</article-title>
<source>BMJ</source>
<volume>322</volume>
<fpage>1567</fpage>
<lpage>1572</lpage>
<pub-id pub-id-type="pmid">11431296</pub-id></element-citation></ref><ref id="pone.0005318-Shekalaghe1"><label>32</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Shekalaghe</surname><given-names>S</given-names></name><name><surname>Drakeley</surname><given-names>C</given-names></name><name><surname>Gosling</surname><given-names>R</given-names></name><name><surname>Ndaro</surname><given-names>A</given-names></name><name><surname>van Meegeren</surname><given-names>M</given-names></name><etal/></person-group>
<year>2007</year>
<article-title>Primaquine clears submicroscopic <italic>Plasmodium falciparum</italic> gametocytes that persist after treatment with sulphadoxine-pyrimethamine and artesunate.</article-title>
<source>PLoS One</source>
<volume>10</volume>
<fpage>e1023</fpage>
</element-citation></ref><ref id="pone.0005318-Okell1"><label>33</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Okell</surname><given-names>LC</given-names></name><name><surname>Drakeley</surname><given-names>CJ</given-names></name><name><surname>Ghani</surname><given-names>AC</given-names></name><name><surname>Bousema</surname><given-names>T</given-names></name><name><surname>Sutherland</surname><given-names>CJ</given-names></name></person-group>
<year>2008</year>
<article-title>Reduction of transmission from malaria patients by artemisinin combination therapies: a pooled analysis of six randomized trials.</article-title>
<source>Malaria J</source>
<volume>7</volume>
<fpage>125</fpage>
</element-citation></ref><ref id="pone.0005318-Henderson1"><label>34</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Henderson</surname><given-names>LH</given-names></name></person-group>
<year>1934</year>
<article-title>Prophylaxis of malaria in the Sudan, with special reference to the use of plasmoquine.</article-title>
<source>Trans R Soc Trop Med Hyg</source>
<volume>28</volume>
<fpage>157</fpage>
<lpage>164</lpage>
</element-citation></ref><ref id="pone.0005318-Barber1"><label>35</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Barber</surname><given-names>MA</given-names></name></person-group>
<year>1932</year>
<article-title>Malaria studies on the Firestone rubber plantation in Liberia, West Africa.</article-title>
<source>Am J Hyg</source>
<volume>15</volume>
<fpage>601</fpage>
<lpage>633</lpage>
</element-citation></ref><ref id="pone.0005318-Anonymous1"><label>36</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Anonymous</surname></name></person-group>
<year>1933</year>
<article-title>The Therapeutics of Malaria. Third General Report of the Malaria Commission.</article-title>
<source>Quarterly Bulletin of the Health Organisation of the League of Nations</source>
<volume>2</volume>
<fpage>181</fpage>
<lpage>28</lpage>
</element-citation></ref><ref id="pone.0005318-Rieckmann1"><label>37</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Rieckmann</surname><given-names>KH</given-names></name><name><surname>McNamara</surname><given-names>JV</given-names></name><name><surname>Kass</surname><given-names>L</given-names></name><name><surname>Powell</surname><given-names>RD</given-names></name></person-group>
<year>1969</year>
<article-title>Gametocytocidal and sporonticidal effects of primaquine upon two strains of Plasmodium falciparum.</article-title>
<source>Military Medicine</source>
<volume>134</volume>
<fpage>802</fpage>
<lpage>19</lpage>
<pub-id pub-id-type="pmid">4987059</pub-id></element-citation></ref><ref id="pone.0005318-Arnold1"><label>38</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Arnold</surname><given-names>J</given-names></name><name><surname>Alving</surname><given-names>AS</given-names></name><name><surname>Hockwald</surname><given-names>RS</given-names></name><name><surname>Clayman</surname><given-names>CB</given-names></name><name><surname>Dern</surname><given-names>RJ</given-names></name><etal/></person-group>
<year>1955</year>
<article-title>The antimalarial action of primaquine against the blood and tissue stages of falciparum malaria (Panama, P-F-6 starin).</article-title>
<source>J Lab Clin Med</source>
<volume>46</volume>
<fpage>391</fpage>
<lpage>397</lpage>
<pub-id pub-id-type="pmid">13252317</pub-id></element-citation></ref><ref id="pone.0005318-Gogtay1"><label>39</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gogtay</surname><given-names>NJ</given-names></name><name><surname>Chogle</surname><given-names>AR</given-names></name><name><surname>Sorabjee</surname><given-names>JS</given-names></name><name><surname>Marathe</surname><given-names>SN</given-names></name><name><surname>Kshirsagar</surname><given-names>NA</given-names></name></person-group>
<year>1999</year>
<article-title>Poor gametocytocidal activity of 45 mg primaquine in chloroquine-treated patients with acute, uncomplicated, <italic>Plasmodium falciparum</italic> malaria in Mumbai (Bombay): an issue of public-health importance.</article-title>
<source>Ann Trop Med Parasitol</source>
<volume>93</volume>
<fpage>813</fpage>
<lpage>6</lpage>
<pub-id pub-id-type="pmid">10715674</pub-id></element-citation></ref><ref id="pone.0005318-Akoachere1"><label>40</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Akoachere</surname><given-names>M</given-names></name><name><surname>Buchholz</surname><given-names>K</given-names></name><name><surname>Fischer</surname><given-names>E</given-names></name><name><surname>Burhenne</surname><given-names>J</given-names></name><name><surname>Haefeli</surname><given-names>WE</given-names></name><etal/></person-group>
<year>2005</year>
<article-title>In vitro assessment of methylene blue on chloroquine-sensitive and &#x02013;resistant <italic>Plasmodium falciparum</italic> strains reveals synergistic action with artemisinins.</article-title>
<source>Antimicrob Agents Chemother</source>
<volume>49</volume>
<fpage>4592</fpage>
<lpage>97</lpage>
<pub-id pub-id-type="pmid">16251300</pub-id></element-citation></ref></ref-list></back></article>